<p>SD: Standard deviation; IQR: Inter-quartile range; AD: Alzheimer's disease; VAD: Vascular dementia; DLB: Dementia with Lewy bodies; PDD: Parkinson's disease dementia; PD: Parkinson's disease. Denominators are given for prevalence (%) where data is incomplete.</p>*<p>Control vs. patients p = 0.457; Control vs. AD p = 0.036; control vs. VAD p = 0.027; Control vs. DLB p = 0.945; Control vs. PDD p = 0.031.</p>**<p>Control vs. all patient groups p<0.001. No significant differences between patient groups.</p>***<p>Control vs. AD p = 0.087; control vs. VAD p = 0.009; Control vs. DLB p = 0.005; Control vs. PDD p<0.001</p>†<p>Control vs. AD p = 0.013; control vs. VAD p<0.001; Control vs. DLB p = 0.001; Control vs. PDD p<0.001</p>††<p>Control vs. ...
INTRODUCTION: Large studies on cognitive profiles of patients with mild cognitive impairment (MCI) d...
Objective: Parkinson’s disease with mild cognitive impairment (PD-MCI) is a risk factor for progress...
Objective: To compare Neuropsychiatric symptoms (NPS) in participants with Parkinson’s disease (PD),...
<p>Two-sample <i>t</i>-tests were used for group-wise comparisons of baseline scores and progression...
BACKGROUND: The relation between dementia with Lewy bodies (DLB) and Parkinson's disease with dement...
Background: Greater understanding of differences in baseline impairment and disease progression in p...
<p>NS: Not significant, NA: Not analyzed, AD: Alzheimer’s disease, IPD: Idiopathic Parkinson’s disea...
<p>Demographic and clinical characteristics of cognitively normal PD patients (PD-CN) and cognitivel...
<p>Data are presented as mean, standard deviation, number and percentage.</p><p><b>HADS</b>: Hospita...
IntroductionNo known studies have compared longitudinal characteristics between individuals with inc...
<p>PD-NC, Parkinson's disease-Normal Cognition; PD-MCI, Parkinson's disease-Mild Cognitive Impairmen...
a<p>HC vs. PD-NC;</p>b<p>PD-NC vs PD-MCI;</p>c<p>PD-MCI vs. PDD. PD-NC: Parkinson’s disease with nor...
Comparable to Alzheimer’s disease, mild cognitive impairment in Parkinson’s disease (PD-MCI) is asso...
<p><i>* = p<0.05 vs control</i>, n = number, UPDRS: Unified Parkinson's Disease Rating Scale, PD: ...
The Movement Disorder Society Task Force (MDS-TF) has proposed diagnostic criteria for mild cognitiv...
INTRODUCTION: Large studies on cognitive profiles of patients with mild cognitive impairment (MCI) d...
Objective: Parkinson’s disease with mild cognitive impairment (PD-MCI) is a risk factor for progress...
Objective: To compare Neuropsychiatric symptoms (NPS) in participants with Parkinson’s disease (PD),...
<p>Two-sample <i>t</i>-tests were used for group-wise comparisons of baseline scores and progression...
BACKGROUND: The relation between dementia with Lewy bodies (DLB) and Parkinson's disease with dement...
Background: Greater understanding of differences in baseline impairment and disease progression in p...
<p>NS: Not significant, NA: Not analyzed, AD: Alzheimer’s disease, IPD: Idiopathic Parkinson’s disea...
<p>Demographic and clinical characteristics of cognitively normal PD patients (PD-CN) and cognitivel...
<p>Data are presented as mean, standard deviation, number and percentage.</p><p><b>HADS</b>: Hospita...
IntroductionNo known studies have compared longitudinal characteristics between individuals with inc...
<p>PD-NC, Parkinson's disease-Normal Cognition; PD-MCI, Parkinson's disease-Mild Cognitive Impairmen...
a<p>HC vs. PD-NC;</p>b<p>PD-NC vs PD-MCI;</p>c<p>PD-MCI vs. PDD. PD-NC: Parkinson’s disease with nor...
Comparable to Alzheimer’s disease, mild cognitive impairment in Parkinson’s disease (PD-MCI) is asso...
<p><i>* = p<0.05 vs control</i>, n = number, UPDRS: Unified Parkinson's Disease Rating Scale, PD: ...
The Movement Disorder Society Task Force (MDS-TF) has proposed diagnostic criteria for mild cognitiv...
INTRODUCTION: Large studies on cognitive profiles of patients with mild cognitive impairment (MCI) d...
Objective: Parkinson’s disease with mild cognitive impairment (PD-MCI) is a risk factor for progress...
Objective: To compare Neuropsychiatric symptoms (NPS) in participants with Parkinson’s disease (PD),...